The company will roll out one million self-test kits and based on consumer demand, it will make 10 million units available per week. The product should be available in retail within 2-3 days. The company plans to make the products available on the Government e-marketplace (GEM).
SII plans to seek restricted emergency use permission of the vaccine in India. The DCGI has granted permission to the Serum Institute of India (SII) to manufacture the Sputnik COVID-19 vaccine in India for examination, test and analysis with certain conditions, official sources said on Friday. The Pune-based firm has collaborated with Gamaleya Research Institute of Epidemiology and Microbiology, Moscow in Russia for developing Sputnik V at its licensed Hadapsar facility. “The DCGI has granted permission to the Serum Institute to manufacture the Sputnik COVID-19 vaccine in India for examination, test and analysis at its licensed Hadapsar facility with certain conditions,” an official source said.
Liability protection to vaccine makers should be prospective not retrospective
Fri, Jun 4 2021 10:48 IST |
0 Views
China to produce over 3 billion Covid vax this year. Image Source: IANS News
Chennai, June 4 : Even though providing protection against liability claims to the vaccine manufacturers as contemplated by the central government seems unconstitutional, if at all it is given then it should be prospective and not retrospective, said an advocate whose client has preferred a claim against Serum Institute of India Private Ltd.
The Cenre is mulling to provide protection from indemnity protection to Pfizer and Moderna in case of adverse effects on people administered with their Covid-19 vaccine.